Mucosat, 100 mg/ml 2 ml 5 pcs

Pharmacotherapeutic group

Tissue repair stimulator.

ATX code M01AX25

Pharmacological action

The drug has chondroprotective, stimulates the regeneration of cartilage tissue, anti-inflammatory action. It participates in the formation of the basic substance of cartilage and bone tissue, improves phosphorus-calcium metabolism in cartilage tissue, inhibits enzymes that disrupt the structure and functions of articular cartilage, and inhibits the process of degeneration of cartilage. Stimulates the synthesis of proteoglycans, normalizes the metabolism of hyaline cartilage, promotes the regeneration of cartilage surfaces and joint capsule. It prevents compression of connective tissue, increases synovial fluid production and mobility of affected joints, reduces associated inflammation and pain, and helps reduce the need for NSAIDs. In degenerative changes of cartilage tissue it is a means of substitution therapy.

Positive effect is observed within 2-3 weeks after initiation of the drug. The therapeutic effect is retained for a long time (3-6 months) after the end of the course of treatment.

Pharmacokinetics:

Chondroitin sulfate sodium is easily absorbed after intramuscular injection. Within 30 minutes it is detected in the blood in significant concentrations: the maximum concentration is reached after 1 hour, then its content over 2 days gradually decreases.

Chondroitin sulfate sodium accumulates mainly in the cartilage.

The synovial membrane is not an obstacle to its penetration into the joint cavity. Within 15 minutes after intramuscular injection sodium chondroitin sulfate is found in synovial fluid, then it enters the articular cartilage where its content reaches a maximum after 48 hours.

Indications

Degenerative-dystrophic diseases of the joints and spine:

– osteoarthritis of peripheral joints;

– intervertebral osteochondrosis and osteoarthrosis.

To accelerate the formation of callus in fractures.

Pharmacological effect

Pharmacotherapeutic group

Tissue repair stimulator.

Code ATX M01AX25

Pharmacological action

The drug has a chondroprotective, stimulating regeneration of cartilage tissue, and anti-inflammatory effect. Participates in the construction of the basic substance of cartilage and bone tissue, improves phosphorus-calcium metabolism in cartilage tissue, inhibits enzymes that disrupt the structure and function of articular cartilage, and inhibits the processes of degeneration of cartilage tissue. Stimulates the synthesis of proteoglycans, normalizes the metabolism of hyaline cartilage, promotes the regeneration of cartilage surfaces and the joint capsule. Prevents compression of connective tissue, increases the production of synovial fluid and mobility of affected joints, reduces associated inflammation and pain, and helps reduce the need for NSAIDs. For degenerative changes in cartilage tissue, it is a means of replacement therapy.

A positive effect is observed within 2-3 weeks after the start of drug administration. The therapeutic effect lasts for a long time (3-6 months) after completion of the course of treatment.

Pharmacokinetics:

Chondroitin sulfate sodium is easily absorbed after intramuscular administration. Within 30 minutes it is found in the blood in significant concentrations: the maximum concentration is reached after 1 hour, then its content gradually decreases over 2 days.

Chondroitin sulfate sodium accumulates mainly in cartilage tissue.

The synovial membrane is not an obstacle to its penetration into the joint cavity. 15 minutes after intramuscular injection of chondroitin, sodium sulfate is found in the synovial fluid, then it enters the articular cartilage, where its content reaches a maximum after 48 hours.

Active ingredient

Chondroitin sulfate

Composition

Active ingredient:

chondroitin sulfate sodium 100 mg;

Excipients:

benzyl alcohol – 9 mg,

water for d/i – up to 1 ml

Pregnancy

Currently, there are no data on the use of Mucosat® during pregnancy and lactation, as well as in children.

Contraindications

Hypersensitivity, tendency to bleeding, thrombophlebitis.

Side Effects

Allergic reactions and hemorrhages at the injection site are possible. In these cases, the drug is discontinued.

Interaction

When undergoing a course of treatment with Mucosat®, caution should be exercised regarding the simultaneous use of direct-acting anticoagulants. It is also possible to enhance the effect of indirect anticoagulants, antiplatelet agents and fibrinolytics.

Storage conditions

In a place protected from light, at a temperature of 0–20 °C.

Shelf life

3 years

Manufacturer

Sintez/Ellara, Russia